CLH2 is a mouse-derived monoclonal antibody specifically targeting MUC5AC, a high-molecular-weight glycoprotein critical in mucosal protection and implicated in cancer diagnostics. This antibody is widely utilized in research and clinical pathology for detecting MUC5AC expression patterns in normal and diseased tissues .
Immunohistochemistry (IHC): Detects MUC5AC in paraffin-embedded tissues (e.g., gastric carcinoma, biliary tract cancers) .
Immunofluorescence (IF)/Flow Cytometry: Identifies MUC5AC in cell lines and fresh tissues .
Western Blot (WB): Validated in studies analyzing mucin expression .
3.2 Diagnostic Utility
CLH2 aids in distinguishing:
Primary ovarian mucinous tumors (MUC5AC+) vs. colorectal adenocarcinomas (MUC5AC-) .
Pancreatic ductal carcinomas (MUC5AC+) vs. normal pancreas (MUC5AC-) .
| Tissue Type | CLH2 Positivity | Study |
|---|---|---|
| Intrahepatic cholangiocarcinoma | 93% (high-grade) | Okumura 2020 |
| Gallbladder dysplasia | 53% | Chang 2004 |
| Bile duct adenomas | 90% | Hughes 2010 |
CLH2 detects immature MUC5AC in pre-cancerous lesions (e.g., biliary intraepithelial neoplasia) .
Overexpression correlates with poor prognosis in pancreatic and gastric cancers .
Specificity: Confirmed using CRISPR-generated MUC5AC knockout cell lines .
Reproducibility: Cited in 7+ peer-reviewed studies, including PMC articles .
Limitations: Does not bind heavily glycosylated (mature) MUC5AC, necessitating complementary antibodies for full mucin analysis .
CLH2’s role in identifying MUC5AC overexpression has implications for: